Dr. Jeffrey Kasher, Chair of the DrugDev Advisory Board, shares his strategy on how technology companies can be change agents to improve clinical trials
Important Cookie Information – This message will only appear once.
DrugDev websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and their use, please see our Privacy Policy.
